Category: OrbusNeich
Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of stants whose importation is banned in Germany.
A German court issues a 2nd injunction barring Boston Scientific from importing drug-eluting stents into that country.
OrbusNeich exercises its legal win by blocking the import of Boston Scientific's Promus, Taxus, Omega and Synergy stents into Germany.
OrbusNeich Medical wasted no time in enforcing a patent win against Boston Scientific (NYSE:BSX), announcing that it is blocking German imports of its rival's cardiac stents.
A German court grants a preliminary injunction against Boston Scientific in a legal row with OrbusNeich Medical over a pair of stent patents.
UPDATED April 30, 2013 with analyst's reaction; comment from Boston Scientific.
OrbusNeich Medical said a German court granted a preliminary injunction against Boston Scientific (NYSE:BSX) in a legal war over coronary stent patents.
OrbusNeich sues Boston Scientific in an Irish court over alleged patent infringement involving cardiac stents, adding to the slate of lawsuits already pending in Germany and the Netherlands against rival stent-maker Boston Scientific with a new filing in Ireland.
OrbusNeich continued its global row against medtech titan Boston Scientific (NYSE:BSX) even further, filing a patent infringement lawsuit in Ireland to join ones pending in Germany and the Netherlands.
OrbusNeich files patent infringement lawsuits in Germany and the Netherlands against rival stent-maker Boston Scientific, riding on momentum from a recent win from the European Patent Office.
OrbusNeich is taking a recent patent infringement win against Boston Scientific (NYSE:BSX) even further, filing lawsuits in both Germany and the Netherlands to allege patent infringement over stent technology.
OrbusNeich claims a win in a European patent decision over Boston Scientific in their ongoing war over coronary stent technology.
UPDATED Feb. 13, 2012 with comment from Boston Scientific.
OrbusNeich claimed a win over Boston Scientific (NYSE:BSX) in a European patent battle over stent technology.
